Tammenoms Bakker Juliet 4

What Happened

• Juliet Tammenoms Bakker, a member of the RxSight (RXST) board of directors, received an award of 37,037 restricted stock units (RSUs) on June 17, 2026 (transaction code A = award/grant). No purchase price or cash changed hands; the filing reports an acquisition of contingent RSUs rather than a market buy. The filing does not disclose a dollar value for the award.

Key Details

• Transaction date: 2026-06-17 (Form 4 filed 2026-06-18 — timely filing).
• Amount: 37,037 RSUs; price: N/A (award/grant).
• Shares owned after transaction: not specified in the report.
• Vesting: 100% of the RSUs vest on the earlier of (i) one year after the grant (June 17, 2027) or (ii) the date of the next annual meeting, contingent on continued service as an Outside Director per the 2021 Equity Incentive Plan.
• Holding structure: the RSUs are held by a trust for which the reporting person is Investment Trustee; she disclaims beneficial ownership except to the extent of pecuniary interest (see footnote).
• Exhibit included: Exhibit 24 — Power of Attorney.

Context

• Each RSU represents a contingent right to one share of RxSight common stock upon vesting and any required settlement; this is a typical form of non-cash director compensation and not an open-market purchase or sale. Such awards become meaningful only if and when they vest and convert to shares (and may be subject to tax withholding). This filing signals a grant of equity compensation, not an immediate change in market holdings.